Global Pharmatech, Inc.
GBLP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 18.25 | -2.28 | 35.91 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.29% | -0.09% |
| EV / EBITDA | -1,032.25 | -686.50 | -2,708.69 | -634.28 |
| Quality | ||||
| ROIC | 169.86% | 69.56% | 14.89% | 229.94% |
| Gross Margin | 11.15% | 66.02% | 50.18% | 0.00% |
| Cash Conversion Ratio | -0.22 | 1.44 | -18.64 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 74.43% | – | -72.51% | -100.00% |
| Free Cash Flow Growth | 0.00% | -100.00% | 360.02% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.85 | 0.15 | -0.81 | 0.00 |
| Interest Coverage | -113.24 | -379.56 | -188.73 | -3,236.57 |
| Efficiency | ||||
| Inventory Turnover | 9.90 | 0.74 | 1.25 | 0.00 |
| Cash Conversion Cycle | -145.47 | 1,274.90 | -1,810.79 | 0.00 |